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Abstract
N-acetylcysteine (NAC) has been recently proposed as an adjuvant therapeutic drug for influenza pneumonia in
humans. This proposal is based on its ability to restrict influenza virus replication in vitro and to attenuate the
severity of the disease in mouse models. Although available studies were made with different viruses (human and
avian), published information related to the anti-influenza spectrum of NAC is scarce. In this study, we show that
NAC is unable to alter the course of a fatal influenza pneumonia caused by inoculation of a murinized swine H1N1
influenza virus. NAC was indeed able to inhibit the swine virus in vitro but far less than reported for other strains.
Therefore, susceptibility of influenza viruses to NAC appears to be strain-dependent, suggesting that it cannot be
considered as a universal treatment for influenza pneumonia.
Introduction
About 10 percent of the human population is affected
by influenza annually and several pandemic episodes
have occurred throughout recorded history [1]. This
context explains why continued efforts are made to
identify new therapeutic molecules. Among these, N-
acetylcysteine (NAC), which is commonly used for its
mucolytic activity in humans, was shown to inhibit
influenza virus both in mouse models, alone or in com-
bination, with the A/PR/8 strain [2,3], and in vitro, with
H5N1 strains [4]. Recently, NAC treatment was reported
to reduce symptoms of influenza-like illness in humans
[5] and administration of the dose of 100 mg/kg suppo-
sedly contributed to the success of the treatment of a
patient infected with the 2009 pandemic H1N1 virus [6].
In order to determine whether these successful results
can be extrapolated to other viral strains than A/PR/8
and H5N1 strains, the effect of NAC on the clinical
course and outcome of experimental influenza was
assessed in mice inoculated with a lethal dose of our
murinized swine H1N1 influenza strain [7]. In spite of a
significant but very partial anti-influenza effect in vitro,
neither percent survival nor body weight loss were
altered by NAC treatment in vivo, suggesting that NAC-
susceptibility of influenza A viruses is strain-dependent.
Methods
In vivo study
Two groups of ten 8-wk old female CD-1 mice were
intranasally inoculated with 10 MLD50 of murinized A/
swine/Iowa/4/1976 (H1N1) virus [7]. The first group
received 100 mg/kg NAC (Sigma) daily by gavage, from
day 1 to day 7 post-infection (pi), while the second
received the vehicle only. Clinical status, body weight
(BW) and mortality were recorded daily up to day 14 pi.
Challenge studies were approved by the Belgian Council
for Laboratory Animal Science, under the guidance of
the Institutional Animal Care and Use Committees of
the University of Liège.
In vitro study
Near confluent Vero cells (ATCC CCL-81) were
infected at a multiplicity of infection of 0.01 with a Vero
cell-adapted variant of the A/swine/Iowa/4/1976 (H1N1)
virus in 6-well plates. One hour after infection, fresh
DMEM supplemented with 0.2% bovine serum albumin
(Invitrogen), 2 μg/ml TPCK-treated trypsin (Sigma), and
either 0, 0.5, 1.5 or 2.5 mg/ml of NAC (Sigma) was
added onto the cells. Culture supernatants were har-
vested 48 h after infection and titrated by standard pla-
que assays.
Results and discussion
All mice became obviously sick from day 5 pi onward,
with lethargy, ruffled coat and respiratory distress.
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Percent survival and mean survival time (Figure 1) were
not different between NAC and control groups (p >
0.05, Kaplan-Meier analysis). Moreover, course and
amplitude of BW loss (Figure 2) were similar (p > 0.05,
ANOVA). Altogether, the results therefore show that a
daily dose of 100 mg/kg NAC did not confer protection
against influenza disease in our experimental conditions.
The dose of NAC given here (100 mg/kg) is typically
that used for high dose NAC treatment of human severe
influenza pneumonia in recent clinical trials [6]. Some of
the former studies that have enlighted the protective
efficacy of NAC in mouse models have used an oral
dose of 1000 mg/kg, which suggests that the dose given
here is not sufficient. However, 100 mg/kg NAC is
already considered as a high dose in humans, and 1000
mg/kg is obviously unrealistic for humans because too
close to the LD50 [2,3,8,9]. The fact that a dose of NAC
close to that used here drastically diminished mouse
lung damages in a diesel-enhanced influenza pneumonia
[10] whereas it did not work here rather suggests that
the use of different virus strains results in different sus-
ceptibilities to NAC in vivo.
To examine this hypothesis further, the susceptibility
to NAC of our porcine H1N1 strain was assessed in
vitro by mimicking Geiler and colleagues methodological
approach [4]. We also found a dose-dependent inhibi-
tion of influenza virus replication by NAC (Figure 3).
However, even a very high dose (2.5 mg/ml, about 15
Figure 1 Kaplan-Meier survival analysis after H1N1 virus inoculation in mock- and N-acetylcysteine-treated mice (n = 10).
Figure 2 Effect of mock and N-acetylcysteine oral treatment on body weight course after inoculation of 10 DL50 of H1N1 virus in
mice. Means ± SD (n = 10).
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mM) resulted in a ≈ 6-fold reduction of virus yield,
which is far less than that observed with H5N1 [4].
Thus, the anti-influenza activity of NAC appears to be
strain-dependent as already supposable from previous
studies [4]. The porcine A/swine/Iowa/4/1976 (H1N1)
strain used here seems more resistant to NAC than the
human strains A/PR/8/1934 (H1N1) and A/Hong Kong/
8/1968 (H3N2) used by other authors in mouse models
[2,3,8,10]. The lack of protection in vivo recorded in our
experimental conditions is therefore probably associated
to a combination of the NAC-resistance phenotype and
to the pathotype [7] of the virus strain used.
Overall, the in vitro and in vivo results gathered here
show that susceptibility of influenza viruses to NAC is
clearly strain-dependent, which suggests that NAC can-
not be considered to be a universal treatment for influ-
enza pneumonia. A systematic testing of anti-influenza
activity of NAC should be implemented whenever a new
strain emerges.
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